02/14/2025
8:30 AM | Avoro Capital Advisors LLC (Filed by)
Monte Rosa Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
01/31/2025
5:43 PM | BIOTECHNOLOGY VALUE FUND L P (Filed by)
Monte Rosa Therapeutics (Subject)
| Form SCHEDULE 13G | |
01/30/2025
8:58 PM | Monte Rosa Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SCHEDULE 13G | |
01/10/2025
6:03 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/13/2024
8:00 AM | Hughes Eric A (Reporting)
Monte Rosa Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/13/2024
8:05 AM | Hughes Eric A (Reporting)
Monte Rosa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:03 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2024
6:03 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/07/2024
6:02 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/07/2024
6:07 AM | Monte Rosa Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/30/2024
4:10 PM | Monte Rosa Therapeutics (Subject)
Versant Venture Capital VI, L.P. (Filed by)
| Form SC 13D/A | |
Get the Latest News and Ratings for GLUE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
10/28/2024
3:05 PM | Monte Rosa Therapeutics (Subject)
Wallace Owen B. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/28/2024
5:59 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/24/2024
4:00 PM | Monte Rosa Therapeutics (Subject)
Versant Venture Capital VI, L.P. (Filed by)
| Form SC 13D/A | |
09/24/2024
3:40 PM | Monte Rosa Therapeutics (Issuer)
Versant Vantage I GP, L.P. (Reporting)
Versant Vantage I GP-GP, LLC (Reporting)
Versant Vantage I, L.P. (Reporting)
Versant Venture Capital VI, L.P. (Reporting)
Versant Ventures VI GP, L.P. (Reporting)
Versant Ventures VI GP-GP, LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/13/2024
5:44 PM | Monte Rosa Therapeutics (Issuer)
Versant Vantage I GP, L.P. (Reporting)
Versant Vantage I GP-GP, LLC (Reporting)
Versant Vantage I, L.P. (Reporting)
Versant Venture Capital VI, L.P. (Reporting)
Versant Ventures VI GP, L.P. (Reporting)
Versant Ventures VI GP-GP, LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/13/2024
3:30 PM | Janku Filip (Reporting)
Monte Rosa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/12/2024
6:46 PM | Monte Rosa Therapeutics (Subject)
New Enterprise Associates 17, L.P. (Filed by)
| Form SC 13D/A | |
08/12/2024
4:07 PM | Monte Rosa Therapeutics (Subject)
Versant Venture Capital VI, L.P. (Filed by)
| Form SC 13D/A | |
08/08/2024
6:02 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2024
6:04 AM | Monte Rosa Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/09/2024
3:15 PM | Dunn Edmund (Reporting)
Monte Rosa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
6:04 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/13/2024
7:12 PM | Behbahani Ali (Reporting)
Monte Rosa Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2024
6:18 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2024
7:40 PM | Monte Rosa Therapeutics (Subject)
New Enterprise Associates 17, L.P. (Filed by)
| Form SC 13D/A | |
05/09/2024
6:45 AM | Monte Rosa Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/09/2024
6:05 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/10/2024
3:24 PM | Jones Jullian G (Reporting)
Monte Rosa Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/10/2024
11:58 AM | Monte Rosa Therapeutics (Subject)
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
| Form SC 13G/A | |
03/14/2024
6:44 AM | Monte Rosa Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/14/2024
6:05 AM | Monte Rosa Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
